Fibroblast growth factor receptor 1

SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS® Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium

Retrieved on: 
Wednesday, December 9, 2020
Branches of biology, Biology, Life sciences, Clusters of differentiation, Tyrosine kinase receptors, Biomarkers, Medical statistics, Stem cells, Fibroblast growth factor receptor 1, Fibroblast growth factor receptor 2, Organoid, Breast cancer

SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine , a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derivedtumor organoids, today presented data from a study summarizing the predictive value of the PARIS Test in breast cancer tumors as a poster session (PS04/01) at the 2020 San Antonio Breast Cancer Symposium, taking place virtually from December 8-11, 2020.

Key Points: 
  • SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine , a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derivedtumor organoids, today presented data from a study summarizing the predictive value of the PARIS Test in breast cancer tumors as a poster session (PS04/01) at the 2020 San Antonio Breast Cancer Symposium, taking place virtually from December 8-11, 2020.
  • This study highlighted the utility of the PARIS Test, a CLIA certified functional drug sensitivity assay, to support clinical decision making in heterogeneous disease such as breast cancer.
  • Showed high genomic concordance between known actionable biomarkers, such as PIK3CA and FGFR1/FGFR2, and PARIS Test organoid drug sensitivity.
  • This commitment is exemplified by this exciting data utilizing our PARIS Test across the breast cancer spectrum that showed a very strong predictive value between PARIS Test drug responses and clinical benefit.

DILIsym Services Presents Important DILIsym and NAFLDsym Software Applications at the Virtual AASLD Liver Meeting

Retrieved on: 
Thursday, December 3, 2020
Health, Technology, Software, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Branches of biology, Health care, Pharmacology, Quantitative systems pharmacology, Antivirals, Orphan drugs, Simulations Plus, Antibody, Remdesivir, American Association for the Study of Liver Diseases, Fibroblast growth factor receptor 1, DILIsym Services, Inc., Simulations Plus, Inc.

DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that important applications of their software programs were presented in poster form at the 2020 AASLD virtual Liver Meeting.

Key Points: 
  • DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that important applications of their software programs were presented in poster form at the 2020 AASLD virtual Liver Meeting.
  • Liver safety research conducted with the DILIsym software platform was reported for the COVID-19 drug remdesivir in a poster presented by Dr. Kyunghee Yang.
  • Quantitative systems pharmacology (QSP) work was presented by Dr. Zack Kenz focused on a NAFLDsym software application for the agonist anti-FGFR1/KLB bispecific antibody, BFKB8488A .
  • DILIsym modeling supports key drug development decisions by predicting potential drug-induced liver injury (DILI) risk of new drug candidates.

Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020

Retrieved on: 
Monday, October 26, 2020
Branches of biology, Tyrosine kinase receptors, Angiology, Medical specialties, Clusters of differentiation, Growth factors, Fibroblast growth factor receptor 1, Fibroblast growth factor receptor, Angiogenesis inhibitor, Vascular endothelial growth factor, Angiogenesis

In addition to FGFR1-3 derazantinib also inhibits the vascular endothelial growth factor receptor 2 (VEGFR2).

Key Points: 
  • In addition to FGFR1-3 derazantinib also inhibits the vascular endothelial growth factor receptor 2 (VEGFR2).
  • The presented data from several preclinical models demonstrate that derazantinib has an anti-angiogenic effect, which may contribute to its overall anti-tumor activity in FGFR-driven cancers.
  • Dr. Laurenz Kellenberger, Chief Scientific Officer, said: Our development strategy for derazantinib is focused on strengthening the evidence for its differentiation versus other FGFR inhibitors.
  • The preclinical data on derazantinibs anti-angiogenic activity presented at the conference show that it may provide additional activity on top of its established primary anti-tumor effects in FGFR-positive solid tumors.

Basilea reports pooled efficacy data for derazantinib in iCCA patients with FGFR2 gene mutations and amplifications presented at ESMO MAP Virtual Congress 2020

Retrieved on: 
Monday, October 12, 2020
Clusters of differentiation, Tyrosine kinase receptors, Fibroblast growth factor receptor 2, Organ systems, Syndromes, Clinical medicine, Fibroblast growth factor receptor 1, Beare–Stevenson cutis gyrata syndrome

FGFR inhibitors, including derazantinib, have demonstrated clinical antitumor activity in patients with FGFR2 gene fusion-positive iCCA.

Key Points: 
  • FGFR inhibitors, including derazantinib, have demonstrated clinical antitumor activity in patients with FGFR2 gene fusion-positive iCCA.
  • However, to date there is limited clinical evidence for the benefit of FGFR inhibitors in iCCA patients with FGFR2 gene mutations and amplifications.
  • The data presented at the MAP congress show that derazantinib is active in this group of patients and underscore the broad therapeutic potential of derazantinib in FGFR2-positive iCCA.
  • The following e-poster was presented at the ESMO MAP Virtual Congress 2020:
    Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Pooled analysis of clinical trials and early access programs.

Basilea reports data from poster presentations at ESMO Virtual Congress 2020

Retrieved on: 
Tuesday, September 22, 2020
Tyrosine kinase receptors, Branches of biology, Clusters of differentiation, Basilea Pharmaceutica, Cell biology, Fibroblast growth factor receptor 1, Biology, European Society for Medical Oncology, Fibroblast growth factor receptor, Fibroblast growth factor

Basilea Pharmaceutica Ltd. (SIX: BSLN) today reports on several e-posters with new preclinical and clinical data on its fibroblast growth factor receptor (FGFR) inhibitor derazantinib and its tumor checkpoint controller, lisavanbulin, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which took place from 19-21 September, 2020.

Key Points: 
  • Basilea Pharmaceutica Ltd. (SIX: BSLN) today reports on several e-posters with new preclinical and clinical data on its fibroblast growth factor receptor (FGFR) inhibitor derazantinib and its tumor checkpoint controller, lisavanbulin, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which took place from 19-21 September, 2020.
  • In addition, gastric and lung cancer models showed the strongest correlation of FGFR1-3 expression versus the anticancer activity of derazantinib.
  • The results support the planned clinical investigation of derazantinib in gastric cancer as its next indication.
  • Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics Announce Dosing of First Patient in Investigator-Initiated Phase 0/2 Clinical Trial of Infigratinib in Recurrent Glioblastoma

Retrieved on: 
Tuesday, July 28, 2020
Tyrosine kinase receptors, Fibroblast growth factor receptor 1, Branches of biology, Brain tumor, Tyrosine kinase inhibitor

Infigratinib is an investigational, orally administered, FGFR1-3 selective tyrosine kinase inhibitor being developed by BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate company QED Therapeutics, Inc.

Key Points: 
  • Infigratinib is an investigational, orally administered, FGFR1-3 selective tyrosine kinase inhibitor being developed by BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate company QED Therapeutics, Inc.
  • Patients with successful tumor penetration will receive infigratinib long-term in a Phase 2 expansion arm of the trial.
  • Infigratinib was one of the most promising agents, said Shwetal Mehta, Ph.D., deputy director of the Ivy Brain Tumor Center.
  • Infigratinib was previously tested in an uncontrolled Phase 2 study for recurrent high-grade gliomas, said Nader Sanai, M.D., director of the Ivy Brain Tumor Center.

Taiho Oncology To Present Data on Futibatinib (TAS-120) at the AACR Annual Meeting 2020

Retrieved on: 
Thursday, June 4, 2020
Tyrosine kinase receptors, American Association for Cancer Research, Fibroblast growth factor receptor 1, TAS, Fibroblast growth factor receptor, AACR

PRINCETON, N.J., June 4, 2020 /PRNewswire/ --Taiho Oncology, Inc. today announced that preclinical data for futibatinib (TAS-120) will be presented online during the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020 from June 22-24.

Key Points: 
  • PRINCETON, N.J., June 4, 2020 /PRNewswire/ --Taiho Oncology, Inc. today announced that preclinical data for futibatinib (TAS-120) will be presented online during the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020 from June 22-24.
  • Key presentations include:
    Futibatinib (TAS-120) plus chemotherapy demonstrated a synergistic effect across various FGFR-deregulated cancer cell lines and xenograft models (Abstract 564).
  • Results will be shared online as a poster presentation on June 22, 2020.
  • The abstract for this presentation is available on the AACR website: https://www.abstractsonline.com/pp8/#!/9045/presentation/2469
    Synergistic antitumor activity of futibatinib (TAS-120), a FGFR1-4 inhibitor, and PI3K pathway inhibitors (Abstract 659).

BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific Program

Retrieved on: 
Friday, May 29, 2020
Cancer, Neoplasms, Clinical medicine, Cholangiocarcinoma, Hepatology, RTT, Transitional epithelium, Transitional cell carcinoma, Fibroblast growth factor receptor 1

SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that it will present data at the American Society of Clinical Oncology 2020 Virtual Scientific Program showing clinical advancement for infigratinib, QEDs oral FGFR1-3 inhibitor, in both urothelial carcinoma and cholangiocarcinoma (CCA).

Key Points: 
  • SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that it will present data at the American Society of Clinical Oncology 2020 Virtual Scientific Program showing clinical advancement for infigratinib, QEDs oral FGFR1-3 inhibitor, in both urothelial carcinoma and cholangiocarcinoma (CCA).
  • An analysis of response rates in patients with advanced/unresectable or metastatic urothelial carcinoma based on the amount of prior lines of treatment showed consistent response to infigratinib.
  • All eight patients in the study with upper tract urothelial carcinoma (UTUC) received infigratinib as second-line or later therapy.
  • Moreover, QED Therapeutics operates in a very competitive and rapidly changing environment in which new risks emerge from time to time.

eFFECTOR Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (eFT226) in Patients with Advanced Solid Tumor Malignancies

Retrieved on: 
Tuesday, November 5, 2019
Tyrosine kinase receptors, Branches of biology, Cancer, Medicine, Fibroblast growth factor receptor 1, KRAS, Tyrosine kinase, Fibroblast growth factor receptor 2, ErbB, ERBB3, Pancreatic cancer, HER2/neu

The study will enroll patients with activating mutations, amplifications or fusions in HER2, ERBB3, FGFR1, or FGFR2 receptor tyrosine kinases, or any KRAS mutation subtype.

Key Points: 
  • The study will enroll patients with activating mutations, amplifications or fusions in HER2, ERBB3, FGFR1, or FGFR2 receptor tyrosine kinases, or any KRAS mutation subtype.
  • It will also include pancreatic adenocarcinoma with no molecular typing since the large majority of those patients harbor a KRAS mutation.
  • Zotatifin will be administered as a monotherapy in weekly intravenous infusions in subjects with advanced solid tumor malignancies.
  • The drug is currently being evaluated in a Phase 1/2 clinical trial in patients with solid tumors.

QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia

Retrieved on: 
Thursday, October 17, 2019
Tyrosine kinase receptors, Fibroblast growth factor receptor 1, Fibroblast growth factor receptor, Achondroplasia, Branches of biology, Medical specialties, Medicine

SAN FRANCISCO, Oct. 17, 2019 /PRNewswire/ -- QED Therapeutics, Inc. and parent company BridgeBio Pharma, Inc. (NASDAQ: BBIO) announced today the presentation of preclinical data supporting the potential of low-dose infigratinib for the treatment of achondroplasia.

Key Points: 
  • SAN FRANCISCO, Oct. 17, 2019 /PRNewswire/ -- QED Therapeutics, Inc. and parent company BridgeBio Pharma, Inc. (NASDAQ: BBIO) announced today the presentation of preclinical data supporting the potential of low-dose infigratinib for the treatment of achondroplasia.
  • The preclinical study used a dwarf mouse model (Fgfr3Y367C/+), which mimics achondroplasia.
  • QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven diseases.
  • QED is also evaluating infigratinib in clinical studies for cancers driven by mutations in the FGFR1, 2, or 3 genes.